First Hawaiian Bank Has $259,000 Stock Holdings in Johnson & Johnson $JNJ

First Hawaiian Bank decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 88.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,563 shares of the company's stock after selling 11,896 shares during the period. First Hawaiian Bank's holdings in Johnson & Johnson were worth $259,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Highline Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $47,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson in the first quarter worth approximately $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday. Royal Bank Of Canada increased their price target on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Finally, Barclays increased their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $177.49 on Tuesday. The firm has a market capitalization of $427.46 billion, a price-to-earnings ratio of 18.98, a P/E/G ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The stock has a fifty day moving average of $171.25 and a 200 day moving average of $161.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.